Malignant pleural effusion non-small cell lung adenocarcinoma
Conditions
Interventions
Experimental group:After the diagnosis of concurrent sensitive mutations, oral vumetaxin treatment should be initiated. For those whose pleural effusion remains poorly controlled despite thoracic drai
Sponsors
Jiangmen Central Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Age >= 18 years but = 12 weeks; 8.At least one measurable lesion (according to RECIST 1.1); 9.Signed informed consent obtained; 10.No more than 3 bone metastases.
Exclusion criteria
Exclusion criteria: 1.Complicated with interstitial pneumonia or infectious fever before treatment; 2.Complicated with autoimmune diseases or long-term oral corticosteroid use; 3.Prior history of thoracic radiotherapy or thoracic surgery; 4.Complicated with severe anemia, grade 3 WBC or PLT suppression; 5.Allergic to third-generation TKIs; 6.Obvious respiratory symptoms, intolerant to radiotherapy; 7.Active hepatitis B or hepatitis C infection, or currently undergoing antiviral treatment; patients with a clear history of HBV infection whose HBV DNA is at an undetectable level after previous active treatment may be enrolled; 8.Poor control or continuous progression of pleural effusion after two consecutive months of TKI treatment; 9.Patients with brain metastases or liver metastases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-Free Survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall Survival;Adverse event;Malignant Pleural Effusion Control Rate;Peripheral Blood ctDNA Level;Overall Response Rate;Disease Control Rate; | — |
Countries
China
Contacts
Public ContactLin Xiao
Jiangmen Central Hospital
Outcome results
None listed